Symbols / WINT
WINT Chart
About
Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. Its lead product candidate is istaroxime, which is in Phase 2b clinical trials for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. The company also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trials to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant for the treatment of respiratory disease, disorder, or condition in humans; Rostafuroxin, which is in Phase 2b clinical trials for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activators, which are in preclinical trials for the treatment of chronic and acute heart failure. In addition, it is developing an aPKCi inhibitor, which is in preclinical trials for the treatment of cutaneous malignancies and solid tumors. Windtree Therapeutics, Inc. has a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; a license, development, and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; a license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and a collaboration with Battelle Memorial Institute for the development of its aerosol delivery system. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 337.09K |
| Enterprise Value | 3.62M | Income | -48.83M | Sales | — |
| Book/sh | -0.34 | Cash/sh | 0.01 | Dividend Yield | — |
| Payout | 0.00% | Employees | 14 | IPO | — |
| P/E | 0.00 | Forward P/E | -0.00 | PEG | — |
| P/S | — | P/B | -0.03 | P/C | — |
| EV/EBITDA | -0.24 | EV/Sales | — | Quick Ratio | 0.01 |
| Current Ratio | 0.33 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | 323.08 | EPS next Y | -2.13 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2024-11-26 16:00 | ROA | -42.39% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 33.71M |
| Shs Float | 33.71M | Short Float | 6.25% | Short Ratio | 0.08 |
| Short Interest | — | 52W High | 4.41 | 52W Low | 0.01 |
| Beta | 0.66 | Avg Volume | 362.81K | Volume | 101.11K |
| Target Price | — | Recom | None | Prev Close | $0.01 |
| Price | $0.01 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.01
Latest analyst target
3. DCF / Fair value
$-12.63
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.01
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-12-04 | reit | HC Wainwright & Co. | Neutral → Neutral | $7 |
| 2024-01-03 | init | HC Wainwright & Co. | — → Neutral | $1 |
- Windtree Therapeutics (WINT) signs LOI to acquire fintech lender CommLoan - Stock Titan Wed, 03 Dec 2025 08
- Why WINT Stock is Surging? - StocksToTrade Mon, 14 Jul 2025 07
- Windtree Therapeutics Announces Strategic Partnership with Kraken for BNB Crypto Treasury Strategy - Quiver Quantitative ue, 22 Jul 2025 07
- Windtree Therapeutics settles real estate dispute, receives $750,000 from escrow - Investing.com Mon, 06 Oct 2025 07
- Windtree Therapeutics Faces Nasdaq Delisting Notice - TipRanks Wed, 20 Aug 2025 07
- Heart failure drug lineup sold, but seller keeps a slice of future sales - Stock Titan ue, 23 Dec 2025 08
- BNB hits all-time high as Windtree faces Nasdaq delisting, WINT plunges - FXStreet hu, 21 Aug 2025 07
- WLFI Project Overview: Will BNB Microstrategy Windtree, which has been required by NASDAQ to delist, face a similar situation as $WLFI? - Binance hu, 21 Aug 2025 07
- Windtree Therapeutics, Inc. Announces Up to $700 Million Commitment for BNB Acquisitions to Enhance Cryptocurrency Treasury Strategy - Nasdaq hu, 24 Jul 2025 07
- WINT stock touches 52-week low at $1.1 amid steep annual decline - Investing.com Wed, 16 Apr 2025 07
- Windtree Eliminates 99% of Preferred C Shares as BNB Crypto Strategy Sees 17% Gain - Stock Titan ue, 29 Jul 2025 07
- Windtree Therapeutics: The Next Big Move? - StocksToTrade hu, 17 Jul 2025 07
- Windtree Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - Nasdaq Mon, 24 Mar 2025 07
- Windtree Therapeutics announces resignation of chief medical officer - Investing.com Mon, 08 Sep 2025 07
- Windtree Makes Historic Move: Secures $60M to Become First NASDAQ-Listed BNB Crypto Player - Stock Titan Wed, 16 Jul 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 5431 | 4942 | — | Purchase at price 0.91 per share. | FRASER CRAIG E | Chief Executive Officer | — | 2024-10-08 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 79.64K | 0.00 | -631.50K | -5.79M |
| TaxRateForCalcs | 0.00 | 0.00 | 0.03 | 0.13 |
| NormalizedEBITDA | -25.27M | -17.10M | -21.25M | -32.30M |
| TotalUnusualItems | 23.80M | -3.06M | -18.74M | -45.02M |
| TotalUnusualItemsExcludingGoodwill | 23.80M | -3.06M | -18.74M | -45.02M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -1.79M | -20.29M | -39.21M | -67.64M |
| ReconciledDepreciation | 84.00K | 82.00K | 533.00K | 192.00K |
| EBITDA | -1.47M | -20.16M | -39.99M | -77.32M |
| EBIT | -1.56M | -20.24M | -40.52M | -77.51M |
| NetInterestIncome | -165.00K | 275.00K | 56.00K | -23.00K |
| InterestExpense | 235.00K | 50.00K | 53.00K | 114.00K |
| InterestIncome | 70.00K | 325.00K | 109.00K | 91.00K |
| NormalizedIncome | -25.51M | -17.23M | -21.10M | -28.41M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -1.79M | -20.29M | -39.21M | -67.64M |
| TotalExpenses | 25.02M | 17.54M | 21.89M | 32.26M |
| TotalOperatingIncomeAsReported | -26.14M | -20.60M | -41.33M | -77.28M |
| DilutedAverageShares | 52.58K | 4.30K | 858.00 | 628.00 |
| BasicAverageShares | 52.58K | 4.30K | 858.00 | 628.00 |
| DilutedEPS | -104.35 | -4.72K | -56.01K | -107.70K |
| BasicEPS | -104.35 | -4.72K | -45.70K | -107.70K |
| DilutedNIAvailtoComStockholders | -5.49M | -20.29M | -39.21M | -67.64M |
| NetIncomeCommonStockholders | -5.49M | -20.29M | -39.21M | -67.64M |
| PreferredStockDividends | 3.70M | |||
| NetIncome | -1.79M | -20.29M | -39.21M | -67.64M |
| NetIncomeIncludingNoncontrollingInterests | -1.79M | -20.29M | -39.21M | -67.64M |
| NetIncomeContinuousOperations | -1.79M | -20.29M | -39.21M | -67.64M |
| TaxProvision | -6.00K | 0.00 | -1.37M | -9.99M |
| PretaxIncome | -1.79M | -20.29M | -40.58M | -77.62M |
| OtherIncomeExpense | 23.39M | -3.03M | -18.74M | -45.34M |
| OtherNonOperatingIncomeExpenses | -408.00K | 31.00K | 2.00K | -320.00K |
| SpecialIncomeCharges | 13.32M | -3.06M | -19.44M | -45.02M |
| OtherSpecialCharges | -14.44M | |||
| ImpairmentOfCapitalAssets | 1.12M | 3.06M | 19.44M | 45.02M |
| GainOnSaleOfSecurity | 10.48M | 700.00K | ||
| NetNonOperatingInterestIncomeExpense | -165.00K | 275.00K | 56.00K | -23.00K |
| InterestExpenseNonOperating | 235.00K | 50.00K | 53.00K | 114.00K |
| InterestIncomeNonOperating | 70.00K | 325.00K | 109.00K | 91.00K |
| OperatingIncome | -25.02M | -17.54M | -21.89M | -32.26M |
| OperatingExpense | 25.02M | 17.54M | 21.89M | 32.26M |
| ResearchAndDevelopment | 16.28M | 8.34M | 11.10M | 17.79M |
| SellingGeneralAndAdministration | 8.74M | 9.20M | 10.79M | 14.47M |
| GeneralAndAdministrativeExpense | 8.74M | 9.20M | 10.79M | 14.47M |
| OtherGandA | 8.74M | 9.20M | 10.79M | 14.47M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 1.00 | 0.00 | 0.00 | 0.00 |
| OrdinarySharesNumber | 256.40K | 6.66K | 858.00 | 628.00 |
| ShareIssued | 256.40K | 6.66K | 858.00 | 628.00 |
| TotalDebt | 1.82M | 1.83M | 2.28M | 2.89M |
| TangibleBookValue | -14.13M | -21.86M | -18.30M | -5.87M |
| InvestedCapital | 10.66M | 3.62M | 10.26M | 42.17M |
| WorkingCapital | -3.14M | 1.38M | 4.92M | 18.57M |
| NetTangibleAssets | -14.13M | -21.86M | -18.30M | -5.87M |
| CapitalLeaseObligations | 1.16M | 1.60M | 2.03M | 2.60M |
| CommonStockEquity | 10.00M | 3.39M | 10.01M | 41.88M |
| TotalCapitalization | 10.00M | 3.39M | 10.01M | 41.88M |
| TotalEquityGrossMinorityInterest | 10.00M | 3.39M | 10.01M | 41.88M |
| StockholdersEquity | 10.00M | 3.39M | 10.01M | 41.88M |
| TreasuryStock | 3.05M | 3.05M | 3.05M | 3.05M |
| RetainedEarnings | -846.61M | -844.82M | -824.53M | -785.32M |
| AdditionalPaidInCapital | 859.66M | 851.27M | 837.60M | 830.26M |
| CapitalStock | 0.00 | 0.00 | 0.00 | 0.00 |
| CommonStock | 0.00 | 0.00 | 0.00 | 0.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 17.88M | 29.02M | 27.94M | 32.91M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 12.16M | 25.02M | 25.48M | 27.98M |
| OtherNonCurrentLiabilities | 3.80M | 18.80M | 18.80M | 18.80M |
| PreferredSecuritiesOutsideStockEquity | 3.18M | 0.00 | 0.00 | 0.00 |
| NonCurrentDeferredLiabilities | 4.53M | 5.06M | 5.06M | 7.11M |
| NonCurrentDeferredTaxesLiabilities | 4.53M | 5.06M | 5.06M | 7.11M |
| LongTermDebtAndCapitalLeaseObligation | 653.00K | 1.16M | 1.62M | 2.07M |
| LongTermCapitalLeaseObligation | 653.00K | 1.16M | 1.62M | 2.07M |
| CurrentLiabilities | 5.72M | 4.00M | 2.46M | 4.92M |
| OtherCurrentLiabilities | 963.00K | 900.00K | ||
| CurrentDebtAndCapitalLeaseObligation | 1.17M | 669.00K | 656.00K | 822.00K |
| CurrentCapitalLeaseObligation | 508.00K | 436.00K | 404.00K | 528.00K |
| CurrentDebt | 661.00K | 233.00K | 252.00K | 294.00K |
| OtherCurrentBorrowings | 333.00K | 233.00K | 252.00K | 294.00K |
| CurrentNotesPayable | 328.00K | 0.00 | ||
| PayablesAndAccruedExpenses | 3.58M | 2.43M | 1.80M | 4.10M |
| CurrentAccruedExpenses | 1.45M | 1.62M | 1.55M | 3.41M |
| Payables | 2.14M | 809.00K | 249.00K | 693.00K |
| TotalTaxPayable | 261.00K | 0.00 | ||
| AccountsPayable | 1.88M | 809.00K | 249.00K | 693.00K |
| TotalAssets | 27.88M | 32.41M | 37.95M | 74.79M |
| TotalNonCurrentAssets | 25.30M | 27.03M | 30.58M | 51.30M |
| OtherNonCurrentAssets | 9.00K | 150.00K | 154.00K | 154.00K |
| GoodwillAndOtherIntangibleAssets | 24.13M | 25.25M | 28.31M | 47.75M |
| OtherIntangibleAssets | 24.13M | 25.25M | 25.25M | 32.07M |
| Goodwill | 0.00 | 3.06M | 15.68M | |
| NetPPE | 1.16M | 1.63M | 2.12M | 3.39M |
| AccumulatedDepreciation | -3.83M | -3.74M | -3.66M | -6.73M |
| GrossPPE | 4.99M | 5.37M | 5.77M | 10.12M |
| Leases | 2.66M | 2.66M | 2.65M | 2.65M |
| OtherProperties | 1.05M | 1.44M | 1.85M | 2.38M |
| MachineryFurnitureEquipment | 1.27M | 1.26M | 1.27M | 5.09M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 2.57M | 5.38M | 7.38M | 23.49M |
| OtherCurrentAssets | 795.00K | 1.06M | 1.21M | 1.14M |
| PrepaidAssets | 1.14M | |||
| CashCashEquivalentsAndShortTermInvestments | 1.78M | 4.32M | 6.17M | 22.35M |
| CashAndCashEquivalents | 1.78M | 4.32M | 6.17M | 22.35M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -15.41M | -13.45M | -19.46M | -23.94M |
| RepurchaseOfCapitalStock | -1.88M | 0.00 | ||
| RepaymentOfDebt | -605.00K | -797.00K | -1.17M | -3.87M |
| IssuanceOfDebt | 1.86M | 0.00 | 0.00 | |
| IssuanceOfCapitalStock | 5.49M | 11.55M | 4.25M | 32.23M |
| CapitalExpenditure | -12.00K | -15.00K | -13.00K | -279.00K |
| EndCashPosition | 1.79M | 4.47M | 6.33M | 22.50M |
| BeginningCashPosition | 4.47M | 6.33M | 22.50M | 17.08M |
| ChangesInCash | -2.68M | -1.86M | -16.18M | 5.42M |
| FinancingCashFlow | 12.73M | 11.60M | 3.08M | 29.36M |
| CashFlowFromContinuingFinancingActivities | 12.73M | 11.60M | 3.08M | 29.36M |
| NetOtherFinancingCharges | 8.52M | 1.00M | ||
| ProceedsFromStockOptionExercised | 0.00 | 843.00K | 0.00 | 0.00 |
| CashDividendsPaid | -657.00K | 0.00 | ||
| PreferredStockDividendPaid | -657.00K | 0.00 | ||
| NetPreferredStockIssuance | -1.88M | 0.00 | ||
| PreferredStockPayments | -1.88M | 0.00 | ||
| NetCommonStockIssuance | 5.49M | 11.55M | 4.25M | 32.23M |
| CommonStockIssuance | 5.49M | 11.55M | 4.25M | 32.23M |
| NetIssuancePaymentsOfDebt | 1.26M | -797.00K | -1.17M | -3.87M |
| NetShortTermDebtIssuance | -455.00K | -797.00K | -1.17M | |
| ShortTermDebtPayments | -455.00K | -797.00K | -1.17M | |
| NetLongTermDebtIssuance | 1.71M | 0.00 | -1.17M | -3.87M |
| LongTermDebtPayments | -150.00K | 0.00 | -1.17M | -3.87M |
| LongTermDebtIssuance | 1.86M | 0.00 | 0.00 | |
| InvestingCashFlow | -12.00K | -15.00K | 197.00K | -279.00K |
| CashFlowFromContinuingInvestingActivities | -12.00K | -15.00K | 197.00K | -279.00K |
| NetPPEPurchaseAndSale | -12.00K | -15.00K | 197.00K | -279.00K |
| SaleOfPPE | 0.00 | 210.00K | 0.00 | |
| PurchaseOfPPE | -12.00K | -15.00K | -13.00K | -279.00K |
| OperatingCashFlow | -15.40M | -13.44M | -19.45M | -23.66M |
| CashFlowFromContinuingOperatingActivities | -15.40M | -13.44M | -19.45M | -23.66M |
| ChangeInWorkingCapital | 1.37M | 2.02M | -1.78M | -58.00K |
| ChangeInOtherCurrentLiabilities | -977.00K | 469.00K | -571.00K | -548.00K |
| ChangeInPayablesAndAccruedExpense | 1.27M | 626.00K | -2.28M | -875.00K |
| ChangeInAccruedExpense | 200.00K | 66.00K | -1.84M | -407.00K |
| ChangeInPayable | 1.07M | 560.00K | -444.00K | -468.00K |
| ChangeInAccountPayable | 1.07M | 560.00K | -444.00K | -468.00K |
| ChangeInPrepaidAssets | 1.08M | 923.00K | 1.08M | 1.36M |
| OtherNonCashItems | 8.68M | 409.00K | 528.00K | 1.17M |
| StockBasedCompensation | 455.00K | 1.28M | 3.09M | 7.24M |
| UnrealizedGainLossOnInvestmentSecurities | 222.00K | 0.00 | ||
| AssetImpairmentCharge | 1.12M | 3.06M | 19.44M | 45.02M |
| DeferredTax | -210.00K | 0.00 | -1.37M | -9.99M |
| DeferredIncomeTax | -210.00K | 0.00 | -1.37M | -9.99M |
| DepreciationAmortizationDepletion | 84.00K | 82.00K | 533.00K | 192.00K |
| DepreciationAndAmortization | 84.00K | 82.00K | 533.00K | 192.00K |
| OperatingGainsLosses | -25.34M | 9.00K | -691.00K | 396.00K |
| GainLossOnInvestmentSecurities | -10.56M | |||
| NetForeignCurrencyExchangeGainLoss | -338.00K | -3.00K | -710.00K | 396.00K |
| GainLossOnSaleOfPPE | 0.00 | 12.00K | 19.00K | 0.00 |
| NetIncomeFromContinuingOperations | -1.79M | -20.29M | -39.21M | -67.64M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for WINT
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|